Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.

Eligibility Criteria Arm A:

• Age 60 years or older.
• New diagnosis of Acute Leukemia or MDS, or suspected diagnosis.
• Able to consent to the study.

Eligibility Criteria Arm B:

• Age 60 years or older with a hematologic malignancy.
• Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy.
• Able to consent to the study.